Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21cip (CDKN1A)

Molecular and Cellular Biology

Volumn 32, Issue 9, 2012, Pages 1633-1644

  Wong, Ping Pui ^a   Miranda, Fabrizio ^a   Chan, Kayi V ^a   Berlato, Chiara ^a   Hurst, Helen C ^a   Scibetta, Angelo G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE DEMETHYLASE; KDM5B PROTEIN; MYC PROTEIN; TFAP2C TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADAPTOR PROTEIN COMPLEX 2; BINDING SITES; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; GENES, MYC; GENETIC LOCI; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REPRESSOR PROTEINS; TRANSCRIPTION FACTOR AP-2;

EID: 84861382062     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06373-11     Document Type: Article

References (41)

1. Abbas T, Dutta A. 2009. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9:400-414.
2. Bamforth SD, et al. 2001. Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking cited2, a new tfap2 coactivator. Nat. Genet. 29(4):469-474.
3. Barrett A, et al. 2007. Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases. Int. J. Cancer 121:265-275.
4. Berlato C, et al. 2011. Alternative TFAP2A isoforms have distinct activities in breast cancer. Breast Cancer Res. 13:R23.
5. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC. 1996. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 13:1701-1707.
6. Braganca J, et al. 2003. Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2. J. Biol. Chem. 278:16021-16029.
7. Braganca J, et al. 2002. Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J. Biol. Chem. 277:8559-8565.
8. Cowling VH, Cole MD. 2006. Mechanism of transcriptional activation by the Myc oncoproteins. Semin. Cancer Biol. 16:242-252.
9. Eckert D, Buhl S, Weber S, Jager R, Schorle H. 2005. The AP-2 family of transcription factors. Genome Biol. 6:246.
10. Eloranta JJ, Hurst HC. 2002. Transcription factor ap-2 interacts with the sumo-conjugating enzyme ubc9 and is sumolated in vivo. J. Biol. Chem. 277(34):30798-30804.
11. Gartel AL, Radhakrishnan SK. 2005. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65:3980-3985.
12. Gartel AL, et al. 2001. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. U. S. A. 98:4510-4515.
13. Gee JM, et al. 2009. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J. Pathol. 217:32-41.
14. Gee JM, Robertson JF, Ellis IO, Nicholson RI, Hurst HC. 1999. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J. Pathol. 189:514-520.
15. Goldfarb DS, Gariepy J, Schoolnik G, Kornberg RD. 1986. Synthetic peptides as nuclear localization signals. Nature 322:641-644.
16. Guler G, et al. 2007. Wwox and Ap2γ expression levels predict tamoxifen response. Clin. Cancer Res. 13:6115-6121.
17. Herkert B, Eilers M. 2010. Transcriptional repression: the dark side of Myc. Genes Cancer 1:580-586.
18. Islam AB, Richter WF, Lopez-Bigas N, Benevolenskaya EV. 2011. Selective targeting of histone methylation. Cell Cycle 10:413-424.
19. Krishnakumar R, Kraus WL. 2010. PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol. Cell 39:736-749.
20. Li L, Greer C, Eisenman RN, Secombe J. 2010. Essential functions of the histone demethylase lid. PLoS Genet. 6:e1001221.
21. Liefke R, et al. 2010. Histone demethylase KDM5A is an integral part of the core Notch-RBP-J. repressor complex. Genes Dev. 24:590-601.
22. Lu PJ, et al. 1999. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J. Biol. Chem. 274:15633-15645.
23. Mukherjee S, Conrad SE. 2005. c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J. Biol. Chem. 280:17617-17625.
24. Pellikainen JM, Kosma VM. 2007. Activator protein-2 in carcinogenesis with a special reference to breast cancer-a mini review. Int. J. Cancer 120:2061-2067.
25. Satoda M, et al. 2000. Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus. Nat. Genet. 25:42-46.
26. Scibetta AG, et al. 2007. Functional analysis of the transcription repressor PLU-1/JARID1B. Mol. Cell. Biol. 27:7220-7235.
27. Scibetta AG, Wong PP, Chan KV, Canosa M, Hurst HC. 2010. Dual association by TFAP2A during activation of the p21cip/CDKN1A promoter. Cell Cycle 9:4525-4532.
28. Secombe J, Li L, Carlos L, Eisenman RN. 2007. The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMycinduced cell growth. Genes Dev. 21:537-551.
29. Seoane J, Le HV, Massague J. 2002. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419:729-734.
30. Sharma SV, et al. 2010. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141:69-80.
31. Shilatifard A. 2008. Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr. Opin. Cell Biol. 20:341-348.
32. Stoetzel C, et al. 2009. Confirmation of TFAP2A gene involvement in branchio-oculo-facial syndrome (BOFS) and report of temporal bone anomalies. Am. J. Med. Genet. A 149A:2141-2146.
33. Tan SK, et al. 2011. AP-2gamma regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J. 30:2569-2581.
34. Tu S, et al. 2008. The ARID domain of the H3K4 demethylase RBP2 binds to a DNA CCGCCC motif. Nat. Struct. Mol. Biol. 15:419-421.
35. Vermeulen M, et al. 2010. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell 142:967-980.
36. Williams CM, et al. 2009. AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene.EMBOJ. 28:3591-3601.
37. Wolfer A, et al. 2010. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc. Natl. Acad. Sci. U. S. A. 107:3698-3703.
38. Xiang Y, et al. 2007. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 104:19226-19231.
39. Yamane K, et al. 2007. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol. Cell 25:801-812.
40. Zeng J, et al. 2010. The histone demethylase RBP2 is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology 138:981-992.
41. Zeng YX, Somasundaram K, el-Deiry WS. 1997. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat. Genet. 15:78-82.